Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 80.0%

Neg 80% Neu 0% Pos 0%

Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.